Two healthcare heavyweights are combining forces to form a technology center they hope will, over the next 10 years, “fundamentally advance the pace” of discovery in medical science and healthcare innovation.

Last week a literature review showed none of 62 high-quality medical AI models ready for translation from academic research to clinical practice. Now comes a similar but separate study confirming the depth of the dashed hopes.

The FDA has granted 510(k) clearance to clinical decision support software that uses AI to detect small but potentially cancerous lesions in the lungs.

The FDA has blessed an AI-packing armband that checks for biometric patterns pointing to possible SARS-CoV-2 infection in individuals with no symptoms.

The European Union has granted CE mark approval to a U.S.-based maker of AI software that aids radiologists in distinguishing between benign and malignant lesions on breast ultrasound images.

The FDA has greenlit an AI algorithm that automatically measures dilation in the heart’s right ventricle on CT images.

Affronts against privacy and equality—real, perceived or ginned up—may fuel lawsuits by patients whose COVID care incorporated AI.

An MIT spinoff based in Boston and Milan in Italy has earned CE certification for software that flags respiratory infection in wearers of the company’s smartwatch devices.